No evidence of residual cancer or metastasis after surgery
Patients must have advanced or metastatic MCC defined as evidence of distant metastasis(es) on imaging\r\n* Patients with locoregionally confined disease are not eligible
Patients with evidence of clinical Tb (unresectable) or M (distant metastasis) according to the AJCC  staging system will be ineligible
Patients with distant metastasis (e.g. spread to distant areas outside the regional lymph nodes, clearly non contiguous areas of bone involvement, or distant metastasis to lung, brain, liver or other visceral organs) are ineligible
Known evidence of distant metastasis.
Any known nodal (N) or distant metastasis (M)
Distant metastasis
Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
Evidence of distant metastasis (M) involvement.
Any evidence of metastasis to distant organs (liver, lung, peritoneum)
No evidence of distant metastasis either prior to or after induction chemotherapy.
No distant metastasis as verified by one of the study investigators
Distant metastasis or adenopathy below the clavicles
Evidence of distant metastases or lymph node metastasis (es) that was not within the radiation field
Distant metastasis or adenopathy below the clavicles
Patients with evidence of liver metastasis are excluded
Distant metastasis
Histologically (archival tissue) confirmed adenocarcinoma of the rectum that begins within  cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with no evidence of distant metastasis
No evidence of distant metastasis either prior to or after induction chemotherapy
Evidence of distant metastasis
Distant metastasis to the lung, bone or brain; typically, most stage  uterine papillary serous cancer (UPSC) is confined to the abdomen on presentation
Any evidence of metastasis to distant organs (liver, lung, peritoneum)
Distant metastasis
Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
Evidence of metastasis
No evidence of distant metastasis
Evidence of distant metastasis apparent prior to randomization
Patients with distant metastasis
Patients must have pathologically-confirmed, previously untreated, stage III-IV (excluding N or T) squamous cell carcinoma of the oropharynx, without evidence of distant metastasis
Definitive clinical or radiographic evidence of distant metastasis or adenopathy below the clavicles
Has local or distant metastasis
Subjects with metastasis limited to the bone only are excluded. However, subjects with current metastasis limited to the bone only and with a history of distant metastasis are eligible. Subjects with current metastasis limited to the bone only and with current breast tissue lesion are eligible.
Any evidence of lymph node or distant metastasis.
Patients with any distant metastasis (liver, lung, bone, brain)
No evidence of distant metastasis either prior to or after induction chemotherapy
Radiographic evidence of regional or distant metastasis at the time of study enrollment or at the time of diagnosis
No clinical, radiographic or other evidence of distant metastasis
Patients with distant metastasis and life expectancy >=  months are eligible
Cannot have distant metastasis (M)
Distant metastasis to organs (local recurrence and regional lymph node recurrence are not considered as distant metastasis) other than bone
Prior radiation to site(s) of distant metastasis of bone
Have confirmed distant metastasis with or without local recurrence
Patients with metastatic BCC, histologic confirmation of distant BCC metastasis
At least  organs involved in metastatic gastric tumor (including at least lung or liver or both) in addition to the site of primary tumor, where metastasis in distant lymph nodes, peritoneal metastasis, and malignant pleural effusion may count as \organs\ in this context
No evidence of distant metastasis either prior to or after induction chemotherapy
Evidence of distant metastasis on upright chest X-ray (CXR), CT or other staging studies
Evidence of distant metastasis
Documented evidence of distant metastasis or locoregional recurrence per required assessments within  days prior to starting study therapy. Note: Histologic confirmation of metastatic disease is not required.
Metastatic disease, including lymph nodes or distant metastasis
No evidence of distant metastasis representing stage IV metastatic disease
Evidence of metastasis
Evidence of distant prostate cancer, i.e., including lymph nodes and/or metastasis of cancer on imaging
Evidence of peritoneal or distant metastasis on preoperative imaging
Evidence of metastasis